Raffaella Gentilella
Overview
Explore the profile of Raffaella Gentilella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Perez L, Boye K, Rosilio M, Jung H, Heitmann E, Norrbacka K, et al.
Diabetes Ther
. 2021 Jun;
12(7):1929-1946.
PMID: 34097244
Introduction: The TROPHIES observational study enrolled patients with type 2 diabetes mellitus (T2DM) initiating their first injectable treatment with the glucagon-like peptide 1 receptor agonists (GLP-1 RAs) dulaglutide or liraglutide....
2.
Federici M, Gentilella R, Corcos A, Torre E, Genovese S
Diabetes Metab Res Rev
. 2021 Apr;
37(7):e3434.
PMID: 33900667
Despite the importance of individualised strategies for patients with type 2 diabetes mellitus (T2DM) and the availability of alternative treatments, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sulphonylureas are still...
3.
Romera I, Conget I, Vazquez L, Gentilella R, Lebrec J, Jodar E, et al.
J Diabetes Complications
. 2020 Mar;
34(7):107575.
PMID: 32220551
Aims: To determine the early benefit:risk balance of dulaglutide versus insulin glargine in patients with type 2 diabetes mellitus (T2DM). Methods: This post hoc analysis used data from a randomized,...
4.
Gentilella R, Sesti G, Vazquez L, Sapin H, Reed V, Romera I, et al.
Diabetes Obes Metab
. 2019 Aug;
21(12):2660-2666.
PMID: 31392822
Aim: To assess the relationship between baseline body mass index (BMI) and glycaemic control in dulaglutide-treated patients, a post hoc analysis was conducted on HbA1c and baseline BMI data from...
5.
Gentilella R, Romera I, Nicolay C, Buzzetti R, Vazquez L, Sesti G
Diabetes Ther
. 2019 May;
10(3):1113-1125.
PMID: 31055780
Introduction: This exploratory post hoc analysis investigated the relative changes in glycated haemoglobin (HbA) in patients with type 2 diabetes mellitus (T2DM) treated with dulaglutide versus active comparators across a...
6.
Boye K, Matza L, Stewart K, Jordan J, Biricolti G, Del Santo S, et al.
J Med Econ
. 2019 Apr;
22(8):806-813.
PMID: 31010349
Several glucagon like peptide-1 (GLP-1) receptor agonists are available as weekly injections for treatment of type 2 diabetes. These medications vary in their injection devices, and these differences could impact...
7.
Bianchi A, Giampietro A, Tartaglione L, Chiloiro S, Gentilella R, Bima C, et al.
J Neuroendocrinol
. 2019 Feb;
31(4):e12692.
PMID: 30712287
In patients with growth hormone (GH) deficiency (GHD), low doses of recombinant human GH (rhGH) have a similar or better long-term clinical effect than higher doses. Pharmacogenetic studies suggest that...
8.
Gentilella R, Pechtner V, Corcos A, Consoli A
Diabetes Metab Res Rev
. 2018 Aug;
35(1):e3070.
PMID: 30156747
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an important class of drugs with a well-established efficacy and safety profile in patients with type 2 diabetes mellitus. Agents in this class...
9.
Matza L, Boye K, Jordan J, Norrbacka K, Gentilella R, Tiebout A, et al.
Patient Prefer Adherence
. 2018 Jun;
12:971-979.
PMID: 29922043
Objectives: Several glucagon-like peptide-1 receptor agonists are administered as weekly injections for treatment of type 2 diabetes (T2D). These medications vary in their injection processes, and a recent study in...
10.
Giorgino F, Penfornis A, Pechtner V, Gentilella R, Corcos A
Patient Prefer Adherence
. 2018 May;
12:707-719.
PMID: 29765207
Adherence to antihyperglycemic medications is often suboptimal in patients with type 2 diabetes, and this can contribute to poor glycemic control, increased hospitalization, and the development of diabetic complications. Reported...